The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization

Kane, Mark; Hadler, Stephen C.; Lee, L.; Shapiro, Craig N.; Cui, Fujiang; Wang, X.; Kumar, Rajeev

doi:10.1016/j.vaccine.2013.03.045

Cited by 39 publications

(43 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 In the pre-survey, we found that infants born at home were rarely in Ningbo; what's more, 'home birth' has been confirmed as one of the important determinants affecting TBD coverage. 27 So, based on the reasons above, we exclude those infants in this study.…”

Section: Discussionmentioning

confidence: 99%

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China

Yang

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Evaluate safety and immunization coverage of a new kind of recombinant Hepatitis B vaccine (HepB) in Ningbo city, China. Two groups were carried out in 2 of 11 randomly selected countries in Ningbo in 2009. All of the infants born from July 1 to December 31, 2009 were enrolled as subjects and received 3 doses of HepB at 0, 1, 6 month. Control group (N D 3452) received current HepB derived from Saccharomyces Cerevisiae Yeast (HepB made by recombinant DNA techniques in Saccharomyces Cerevisiae Yeast, HepB-SCY; 5 mg/0.5 ml per dose) and experimental group (N D 5104) received the new kind of HepB derived from Hansenula polymorpha Yeast (HepB made by recombinant DNA techniques in Hansenula polymorpha Yeast, HepB-HPY; 10 mg/0.5 ml per dose). 3-dose and timely birth dose (TBD) coverage were available and compared between 2 groups. Standard structured questionnaires were applied to record information from parents and hospitals for selecting determinants of coverage. The data were analyzed using stepwise multiple logistic regression models. After each dose, HepB-related adverse events (AEs) and recta-temperature were recorded for 7 days. 3-dose coverage in control group (89.98%) was higher than that in experimental group (x2 D 575.1173, P < 0.0001). TBD coverage in control and experimental group were 98.41% and 98.53%, respectively. No statistically significant difference in TBD coverage was found between 2 groups (x2 D 0.0623, P D 0.8029). A total of 9 local AEs were reported, 4 for control group and 5 for experimental group. The percentages of subjects reporting AEs were similar across the 2 vaccination groups. No serious or immediate reactions were found in this study. From logistic models, receiving 10 mg vaccine (odds ratio [OR]:0.38; 95% confidence interval [95%CI]: 0.34-0.44) and mother migrating from other cities (OR: 0.45; 95%CI: 0.42-0.47) were the determinants for non-acceptance of 3 doses of HepB; infants born from low grade hospitals and native mothers contributed to administrate the TBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China

Yang

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…35 The carrier rate in Chinese children aged <5 years fell from 10% in the 1990s to <1% in 2006 and to 0.32% in 2014. 36 Recently, WHO estimated that the protection rates of the timely birth dose and third dose of hepatitis B vaccine (HepB3) among newborns in China, were 96% and 99%, respectively. 37 Our study showed that hepatitis B vaccination (OR a 0.43, 95% CI 0.34 to 0.53) was the protective factor for hepatitis B, and the same results have been observed in other studies.…”

Section: Influencing Factors Of Hepatitis Bmentioning

confidence: 99%

Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo reveal the prevalence and associated influencing factors of hepatitis B among a rural residential population in Zhejiang, China, in order to help develop specific control strategies.MethodsWe conducted a cross-sectional study among a rural residential population in Zhejiang, China. Stratified multistage cluster sampling was utilised in five districts; a structured questionnaire was used to collect the information such as age, gender, education, occupation, living status, and other health related information of the participants by trained local staff; and the hepatitis B virus (HBV) infection status of the participants was determined by the chemiluminescence immunoassay test. Univariate and multivariate analyses were applied to evaluate the influencing factors of HBV infection. The odds ratio of each related factor was assessed with or without adjustment separately.ResultsThe mean age of the 16 601 participants (7881 males and 8720 females) who completed the survey was 40.28±19.47 years. The positive rate of hepatitis B surface antigen (HBsAg) was 4.04% (95% CI 3.74% to 4.35%), and 3.85% when standardised by age and gender. Univariate analysis showed that age, educational level, occupation, living status, history of hepatitis B examinations, history of blood transfusion, vaccination, family history, coastal living, and district were the potential influencing factors. Multivariate logistic regression indicated that occupation, living status, history of hepatitis B examinations, vaccination and district were the influencing factors. Undertaking a service-based tertiary industry job (ORa 1.19, 95% CI 0.94 to 1.51) and non-single living (ORa 2.84, 95% CI 2.17 to 3.70) might be risk factors, while vaccination (ORa 0.43, 95% CI 0.34 to 0.53) and history of hepatitis B examinations (ORa 0.71, 95% CI 0.48 to 1.03) were potential protective factors.ConclusionsThe prevalence of hepatitis B is at an intermediate epidemic level in a rural residential population in Zhejiang, China. Raising vaccination coverage, especially in adults, is a suitable strategy for the prevention and control of hepatitis B.

show abstract

“…To prevent perinatal transmission, simultaneous administration of HB vaccine with one dose of HBIg is recommended in several countries, including China [24]. However, simultaneous administration of vaccine and HBIg could impair the immune response stimulated by the vaccine [25].…”

Section: Tablementioning

confidence: 99%

Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers

Kang

Chen³

et al. 2015

Vaccine

View full text Add to dashboard Cite

The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization

Cited by 39 publications

References 7 publications

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China

Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study

Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers

Contact Info

Product

Resources

About